C4 Therapeutics Stock Sees Significant Upside Potential with $7 Median Price Target

C4 Therapeutics (NASDAQ:CCCC) is a biopharma company developing products that help degrade disease-causing proteins. Analysts are bullish, with a median price target of $7, suggesting significant upside. The company reported a revenue of $11.016 million in Q4, and has a cash position of $297.1 million, allowing it to fund research initiatives.